CVS Health Corporation (CVS) Rose on Improving Execution and Payer Margin Outlook

2 months ago 20

Ricardo Pillai

Wed, July 22, 2026 astatine 11:03 AM CDT 4 min read

Victory Capital, overseeing the RS Large Cap Value Strategy, released its Q2 2026 capitalist letter. A transcript of the missive tin be downloaded here. The RS Large Cap Value Strategy underperformed the Russell 1000 Value Index successful the 2nd 4th of 2026 arsenic unfavorable banal enactment and assemblage allocation weighed connected comparative performance. U.S. equities remained resilient contempt the Iran conflict, elevated inflation, labour marketplace concerns and uncertainty astir Federal Reserve leadership, with the S&P 500 gaining 15% and the Russell 1000 Value returning 13.9%. Market enactment broadened beyond the Magnificent Seven toward semiconductor, memory, powerfulness and different AI infrastructure beneficiaries, portion investors besides moved down the headdress spectrum, helping the Russell 2000 Value emergence 17.2%. Information Technology returned 80.63%, portion Energy fell 13.77%; banal enactment successful Technology and Industrials and an underweight Technology presumption were cardinal detractors. Looking ahead, the steadfast remains focused connected hazard management, valuation subject and identifying financially strong, out-of-favor oregon misunderstood companies with susceptible management, improving ROIC, charismatic reinvestment opportunities and stock prices beneath estimated intrinsic value. In addition, delight cheque the Strategy's apical 5 holdings to cognize its champion picks successful 2026.

In its second-quarter 2026 capitalist letter, RS Large Cap Value Strategy highlighted CVS Health Corporation (NYSE:CVS). CVS Health Corporation (NYSE:CVS) is simply a starring diversified healthcare services institution successful the United States. On July 21, 2026, CVS Health Corporation (NYSE:CVS) closed astatine $110.60 per share. One-month instrumentality of CVS Health Corporation (NYSE:CVS) was 8.57% and its shares gained 78.82% implicit the past 52 weeks. CVS Health Corporation (NYSE:CVS) has a marketplace capitalization of $141.12 cardinal with a 52-week trading scope betwixt $58.50 - $110.62.

RS Large Cap Value Strategy stated the pursuing regarding CVS Health Corporation (NYSE:CVS) successful its Q2 2026 capitalist letter:

"CVS Health is simply a diversified healthcare services institution with starring positions successful pharmacy benefits management, retail pharmacy, and wellness security (via its Aetna franchise). We initiated our concern successful aboriginal 2025 aft shares had fallen, driven mostly by anterior management's "growth astatine immoderate cost" strategy successful Medicare Advantage. That assertive enlargement coincided with a crisp rebound successful post-COVID aesculapian utilization, starring to important borderline compression. From 2022 to 2024, the Health Care Benefits (HCB) segment's aesculapian payment ratio (medical costs / premium revenue) accrued from 84.0% successful 2022 to 92.5% successful 2024. This weighed heavy connected CB operating margins, which fell from 6.9% successful 2022 to 0.2% successful 2024. During the 2nd quarter, CVS benefited from some company-specific execution and improving manufacture fundamentals. institution reported beardown first-quarter results, raised full-year guidance, and saw S&P revise its recognition outlook from antagonistic to stable. Additionally, Medicare Advantage insurers meaningful tailwind erstwhile The Centers for Medicare & Medicaid Services (CMS) finalized a 2.5% complaint summation for 2027, good supra the initially projected 0.1%, portion caller utilization information constituent to moderating aesculapian outgo trends. The operation of higher reimbursement and easing outgo pressures should enactment a meaningful betterment successful payer margins, and we proceed to spot a credible way to an net summation implicit the adjacent 2 to 3 years. That said, we person trimmed the presumption opportunistically to money different charismatic ideas wrong the portfolio."

Read Entire Article